Cardiovascular disease in the youngest: is it time for precision prevention?

The current paradigm for the primary prevention of cardiovascular diseases in the US and in Europe is based upon absolute risk assessment to guide treatment decision (1,2). Over the years, a number of models were developed to tailor risk estimation to specific populations (see Table 2 in reference 2 for an overview), to limit systematic measurement error due to poor model calibration (3).